{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T13:16:28Z","timestamp":1795266988450,"version":"4.10.3"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T00:00:00Z","timestamp":1593993600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["AG052718"],"award-info":[{"award-number":["AG052718"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["GM115617"],"award-info":[{"award-number":["GM115617"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000967","name":"American Health Assistance Foundation","doi-asserted-by":"publisher","award":["A2009-013"],"award-info":[{"award-number":["A2009-013"]}],"id":[{"id":"10.13039\/100000967","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["IIRG-07-59693"],"award-info":[{"award-number":["IIRG-07-59693"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB877"],"award-info":[{"award-number":["SFB877"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cathepsin D (CatD) is a lysosomal protease that degrades both the amyloid \u03b2-protein (A\u03b2) and the microtubule-associated protein, tau, and has been genetically linked to late-onset Alzheimer disease (AD). Here, we sought to examine the consequences of genetic deletion of CatD on A\u03b2 proteostasis in vivo and to more completely characterize the degradation of A\u03b242 and A\u03b240 by CatD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We quantified A\u03b2 degradation rates and levels of endogenous A\u03b242 and A\u03b240 in the brains of CatD-null (CatD-KO), heterozygous null (CatD-HET), and wild-type (WT) control mice. CatD-KO mice die by ~\u20094\u2009weeks of age, so tissues from younger mice, as well as embryonic neuronal cultures, were investigated. Enzymological assays and surface plasmon resonance were employed to quantify the kinetic parameters (\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>M<\/jats:sub>\n                      ,\n                      <jats:italic>k<\/jats:italic>\n                      <jats:sub>cat<\/jats:sub>\n                      ) of CatD-mediated degradation of monomeric human A\u03b242 vs. A\u03b240, and the degradation of aggregated A\u03b242 species was also characterized. Competitive inhibition assays were used to interrogate the relative inhibition of full-length human and mouse A\u03b242 and A\u03b240, as well as corresponding p3 fragments.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Genetic deletion of CatD resulted in 3- to 4-fold increases in insoluble, endogenous cerebral A\u03b242 and A\u03b240, exceeding the increases produced by deletion of an insulin-degrading enzyme, neprilysin or both, together with readily detectable intralysosomal deposits of endogenous A\u03b242\u2014all by 3\u2009weeks of age. Quite significantly, CatD-KO mice exhibited ~\u200930% increases in A\u03b242\/40 ratios, comparable to those induced by presenilin mutations. Mechanistically, the perturbed A\u03b242\/40 ratios were attributable to pronounced differences in the kinetics of degradation of A\u03b242 vis-\u00e0-vis A\u03b240. Specifically, A\u03b242 shows a low-nanomolar affinity for CatD, along with an exceptionally slow turnover rate that, together, renders A\u03b242 a highly potent competitive inhibitor of CatD. Notably, the marked differences in the processing of A\u03b242 vs. A\u03b240 also extend to p3 fragments ending at positions 42 vs. 40.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings identify CatD as the principal intracellular A\u03b2-degrading protease identified to date, one that regulates A\u03b242\/40 ratios via differential degradation of A\u03b242 vs. A\u03b240. The finding that A\u03b242 is a potent competitive inhibitor of CatD suggests a possible mechanistic link between elevations in A\u03b242 and downstream pathological sequelae in AD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13195-020-00649-8","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T12:04:19Z","timestamp":1594037059000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Cathepsin D regulates cerebral A\u03b242\/40 ratios via differential degradation of A\u03b242 and A\u03b240"],"prefix":"10.1186","volume":"12","author":[{"given":"Caitlin N.","family":"Suire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer O.","family":"Abdul-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Sahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongcheul","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica K.","family":"Brizuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Saftig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis W.","family":"Dickson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrone L.","family":"Rosenberry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7185-4255","authenticated-orcid":false,"given":"Malcolm A.","family":"Leissring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,6]]},"reference":[{"issue":"1","key":"649_CR1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1523\/JNEUROSCI.16-01-00186.1996","volume":"16","author":"AM Cataldo","year":"1996","unstructured":"Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA. Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer\u2019s disease. J Neurosci. 1996;16(1):186\u201399.","journal-title":"J Neurosci"},{"issue":"21","key":"649_CR2","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1093\/hmg\/ddp367","volume":"18","author":"Y Wang","year":"2009","unstructured":"Wang Y, Martinez-Vicente M, Kr\u00fcger U, Kaushik S, Wong E, Mandelkow EM, et al. Tau fragmentation, aggregation and clearance: the dual role of lysosomal processing. Hum Mol Genet. 2009;18(21):4153\u201370.","journal-title":"Hum Mol Genet"},{"key":"649_CR3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1749-6632.1993.tb23037.x","volume":"695","author":"C Haass","year":"1993","unstructured":"Haass C, Hung AY, Schlossmacher MG, Oltersdorf T, Teplow DB, Selkoe DJ. Normal cellular processing of the beta-amyloid precursor protein results in the secretion of the amyloid beta peptide and related molecules. Ann N Y Acad Sci. 1993;695:109\u201316.","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"649_CR4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011884","volume":"5","author":"RA Fuentealba","year":"2010","unstructured":"Fuentealba RA, Liu Q, Zhang J, Kanekiyo T, Hu X, Lee JM, et al. Low-density lipoprotein receptor-related protein 1 (LRP1) mediates neuronal A\u03b242 uptake and lysosomal trafficking. PLoS One. 2010;5(7):e11884.","journal-title":"PLoS One"},{"key":"649_CR5","doi-asserted-by":"publisher","unstructured":"Caballero B, Wang Y, Diaz A, Tasset I, Juste YR, Stiller B, Mandelkow EM, Mandelkow E, Cuervo AM. Interplay of pathogenic forms of human tau with different autophagic pathways. Aging Cell. 2018;17(1):e12692. https:\/\/doi.org\/10.1111\/acel.12692.","DOI":"10.1111\/acel.12692"},{"issue":"9","key":"649_CR6","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrn2194","volume":"8","author":"C Ballatore","year":"2007","unstructured":"Ballatore C, Lee VM, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer\u2019s disease and related disorders. Nat Rev Neurosci. 2007;8(9):663\u201372.","journal-title":"Nat Rev Neurosci"},{"issue":"13","key":"649_CR7","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1097\/00001756-199609020-00021","volume":"7","author":"JR McDermott","year":"1996","unstructured":"McDermott JR, Gibson AM. Degradation of Alzheimer\u2019s beta-amyloid protein by human cathepsin D. Neuroreport. 1996;7(13):2163\u20136.","journal-title":"Neuroreport."},{"issue":"2\u20133","key":"649_CR8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-5793(96)01087-3","volume":"396","author":"H Hamazaki","year":"1996","unstructured":"Hamazaki H. Cathepsin D is involved in the clearance of Alzheimer\u2019s beta-amyloid protein. FEBS Lett. 1996;396(2\u20133):139\u201342.","journal-title":"FEBS Lett"},{"issue":"5","key":"649_CR9","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1046\/j.1471-4159.1997.69052026.x","volume":"69","author":"A Kenessey","year":"1997","unstructured":"Kenessey A, Nacharaju P, Ko LW, Yen SH. Degradation of tau by lysosomal enzyme cathepsin D: implication for Alzheimer neurofibrillary degeneration. J Neurochem. 1997;69(5):2026\u201338.","journal-title":"J Neurochem"},{"issue":"4","key":"649_CR10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2174\/187153009789839174","volume":"9","author":"A Vashishta","year":"2009","unstructured":"Vashishta A, Ohri SS, Vetvicka V. Pleiotropic effects of cathepsin D. Endocr Metab Immune Disord Drug Targets. 2009;9(4):385\u201391.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"6","key":"649_CR11","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1086\/504159","volume":"78","author":"R Steinfeld","year":"2006","unstructured":"Steinfeld R, Reinhardt K, Schreiber K, Hillebrand M, Kraetzner R, Bruck W, et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006;78(6):988\u201398.","journal-title":"Am J Hum Genet"},{"issue":"12","key":"649_CR12","doi-asserted-by":"crossref","first-page":"2786","DOI":"10.1093\/emboj\/19.12.2786","volume":"19","author":"J Tyynela","year":"2000","unstructured":"Tyynela J, Sohar I, Sleat DE, Gin RM, Donnelly RJ, Baumann M, et al. A mutation in the ovine cathepsin D gene causes a congenital lysosomal storage disease with profound neurodegeneration. EMBO J. 2000;19(12):2786\u201392.","journal-title":"EMBO J"},{"issue":"4","key":"649_CR13","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1136\/jnnp.2005.063917","volume":"77","author":"Y Davidson","year":"2006","unstructured":"Davidson Y, Gibbons L, Pritchard A, Hardicre J, Wren J, Tian J, et al. Genetic associations between cathepsin D exon 2 C\u2192T polymorphism and Alzheimer\u2019s disease, and pathological correlations with genotype. J Neurol Neurosurg Psychiatry. 2006;77(4):515\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"649_CR14","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/00001756-200207190-00015","volume":"13","author":"A Papassotiropoulos","year":"2002","unstructured":"Papassotiropoulos A, Lewis HD, Bagli M, Jessen F, Ptok U, Schulte A, et al. Cerebrospinal fluid levels of \u03b2-amyloid(42) in patients with Alzheimer\u2019s disease are related to the exon 2 polymorphism of the cathepsin D gene. Neuroreport. 2002;13(10):1291\u20134.","journal-title":"Neuroreport."},{"issue":"6","key":"649_CR15","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/humu.20326","volume":"27","author":"M Riemenschneider","year":"2006","unstructured":"Riemenschneider M, Blennow K, Wagenpfeil S, Andreasen N, Prince JA, Laws SM, et al. The cathepsin D rs17571 polymorphism: effects on CSF tau concentrations in Alzheimer disease. Hum Mutat. 2006;27(6):532\u20137.","journal-title":"Hum Mutat"},{"key":"649_CR16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/978-0-387-35135-3_10","volume-title":"Alzheimer\u2019s disease: advances in genetics, molecular and cellular biology","author":"MA Leissring","year":"2007","unstructured":"Leissring MA, Saido TC. A\u03b2 degradation. In: Sisodia S, Tanzi R, editors. Alzheimer\u2019s disease: advances in genetics, molecular and cellular biology. New York: Springer Publishing Company; 2007. p. 157\u201378."},{"issue":"18","key":"649_CR17","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1111\/bph.14593","volume":"176","author":"NN Nalivaeva","year":"2019","unstructured":"Nalivaeva NN, Turner AJ. Targeting amyloid clearance in Alzheimer\u2019s disease as a therapeutic strategy. Br J Pharmacol. 2019;176(18):3447\u201363.","journal-title":"Br J Pharmacol"},{"issue":"2","key":"649_CR18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/72237","volume":"6","author":"N Iwata","year":"2000","unstructured":"Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, et al. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med. 2000;6(2):143\u201350.","journal-title":"Nat Med"},{"issue":"5521","key":"649_CR19","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","volume":"292","author":"N Iwata","year":"2001","unstructured":"Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, et al. Metabolic regulation of brain A\u03b2 by neprilysin. Science. 2001;292(5521):1550\u20132.","journal-title":"Science."},{"issue":"1","key":"649_CR20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2353\/ajpath.2007.070105","volume":"171","author":"W Farris","year":"2007","unstructured":"Farris W, Schutz SG, Cirrito JR, Shankar GM, Sun X, George A, et al. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol. 2007;171(1):241\u201351.","journal-title":"Am J Pathol"},{"issue":"7","key":"649_CR21","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1073\/pnas.0230450100","volume":"100","author":"W Farris","year":"2003","unstructured":"Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, et al. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A. 2003;100(7):4162\u20137.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"649_CR22","doi-asserted-by":"crossref","first-page":"6221","DOI":"10.1073\/pnas.1031520100","volume":"100","author":"BC Miller","year":"2003","unstructured":"Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sci U S A. 2003;100(10):6221\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"649_CR23","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0896-6273(03)00787-6","volume":"40","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, Sun X, et al. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron. 2003;40(6):1087\u201393.","journal-title":"Neuron."},{"issue":"7","key":"649_CR24","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1523\/JNEUROSCI.2984-08.2009","volume":"29","author":"WJ Meilandt","year":"2009","unstructured":"Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, et al. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic A\u03b2 oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci. 2009;29(7):1977\u201386.","journal-title":"J Neurosci"},{"issue":"1","key":"649_CR25","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2353\/ajpath.2010.090915","volume":"177","author":"Z Ahmed","year":"2010","unstructured":"Ahmed Z, Sheng H, Xu YF, Lin WL, Innes AE, Gass J, et al. Accelerated lipofuscinosis and ubiquitination in granulin knockout mice suggest a role for progranulin in successful aging. Am J Pathol. 2010;177(1):311\u201324.","journal-title":"Am J Pathol"},{"issue":"15","key":"649_CR26","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1002\/j.1460-2075.1995.tb00029.x","volume":"14","author":"P Saftig","year":"1995","unstructured":"Saftig P, Hetman M, Schmahl W, Weber K, Heine L, Mossmann H, et al. Mice deficient for the lysosomal proteinase cathepsin D exhibit progressive atrophy of the intestinal mucosa and profound destruction of lymphoid cells. EMBO J. 1995;14(15):3599\u2013608.","journal-title":"EMBO J"},{"key":"649_CR27","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.biochi.2015.07.020","volume":"122","author":"A Ketscher","year":"2016","unstructured":"Ketscher A, Ketterer S, Dollwet-Mack S, Reif U, Reinheckel T. Neuroectoderm-specific deletion of cathepsin D in mice models human inherited neuronal ceroid lipofuscinosis type 10. Biochimie. 2016;122:219\u201326.","journal-title":"Biochimie."},{"issue":"1","key":"649_CR28","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1023\/A:1027325304203","volume":"22","author":"JR McDermott","year":"1997","unstructured":"McDermott JR, Gibson AM. Degradation of Alzheimer\u2019s beta-amyloid protein by human and rat brain peptidases: involvement of insulin-degrading enzyme. Neurochem Res. 1997;22(1):49\u201356.","journal-title":"Neurochem Res"},{"issue":"8","key":"649_CR29","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/nm0896-864","volume":"2","author":"D Scheuner","year":"1996","unstructured":"Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, et al. Secreted amyloid \u03b2-protein similar to that in the senile plaques of Alzheimer\u2019s disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer\u2019s disease. Nat Med. 1996;2(8):864\u201370.","journal-title":"Nat Med"},{"issue":"4","key":"649_CR30","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1074\/jbc.C200642200","volume":"278","author":"EA Eckman","year":"2003","unstructured":"Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer\u2019s disease \u03b2-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. J Biol Chem. 2003;278(4):2081\u20134.","journal-title":"J Biol Chem"},{"issue":"1","key":"649_CR31","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0925-4439(00)00043-0","volume":"1502","author":"TE Golde","year":"2000","unstructured":"Golde TE, Eckman CB, Younkin SG. Biochemical detection of A\u03b2 isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer\u2019s disease. Biochim Biophys Acta. 2000;1502(1):172\u201387.","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"649_CR32","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nm0197-67","volume":"3","author":"M Citron","year":"1997","unstructured":"Citron M, Westaway D, Xia W, Carlson G, Diehl T, Levesque G, et al. Mutant presenilins of Alzheimer\u2019s disease increase production of 42-residue amyloid \u03b2-protein in both transfected cells and transgenic mice. Nat Med. 1997;3(1):67\u201372.","journal-title":"Nat Med"},{"issue":"6","key":"649_CR33","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","volume":"12","author":"R Cacace","year":"2016","unstructured":"Cacace R, Sleegers K, Van Broeckhoven C. Molecular genetics of early-onset Alzheimer\u2019s disease revisited. Alzheimer\u2019s Dementia. 2016;12(6):733\u201348.","journal-title":"Alzheimer\u2019s Dementia"},{"issue":"3","key":"649_CR34","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1093\/brain\/103.3.695","volume":"103","author":"LW Duchen","year":"1980","unstructured":"Duchen LW, Eicher EM, Jacobs JM, Scaravilli F, Teixeira F. Hereditary leucodystrophy in the mouse: the new mutant twitcher. Brain. 1980;103(3):695\u2013710.","journal-title":"Brain."},{"issue":"Pt 2","key":"649_CR35","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/brain\/106.2.405","volume":"106","author":"H Igisu","year":"1983","unstructured":"Igisu H, Shimomura K, Kishimoto Y, Suzuki K. Lipids of developing brain of twitcher mouse. An authentic murine model of human Krabbe disease. Brain. 1983;106(Pt 2):405\u201317.","journal-title":"Brain."},{"issue":"12","key":"649_CR36","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1523\/JNEUROSCI.22-12-04885.2002","volume":"22","author":"M Taniike","year":"2002","unstructured":"Taniike M, Mohri I, Eguchi N, Beuckmann CT, Suzuki K, Urade Y. Perineuronal oligodendrocytes protect against neuronal apoptosis through the production of lipocalin-type prostaglandin D synthase in a genetic demyelinating model. J Neurosci. 2002;22(12):4885\u201396.","journal-title":"J Neurosci"},{"issue":"44","key":"649_CR37","doi-asserted-by":"crossref","first-page":"27241","DOI":"10.1074\/jbc.271.44.27241","volume":"271","author":"P Saftig","year":"1996","unstructured":"Saftig P, Peters C, von Figura K, Craessaerts K, Van Leuven F, De Strooper B. Amyloidogenic processing of human amyloid precursor protein in hippocampal neurons devoid of cathepsin D. J Biol Chem. 1996;271(44):27241\u20134.","journal-title":"J Biol Chem"},{"issue":"6","key":"649_CR38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neuron.2006.07.027","volume":"51","author":"S Mueller-Steiner","year":"2006","unstructured":"Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer\u2019 disease. Neuron. 2006;51(6):703\u201314.","journal-title":"Neuron."},{"issue":"19","key":"649_CR39","doi-asserted-by":"crossref","first-page":"6115","DOI":"10.1021\/bi015985r","volume":"41","author":"MR Nichols","year":"2002","unstructured":"Nichols MR, Moss MA, Reed DK, Lin WL, Mukhopadhyay R, Hoh JH, et al. Growth of \u03b2-amyloid(1-40) protofibrils by monomer elongation and lateral association. Characterization of distinct products by light scattering and atomic force microscopy. Biochemistry. 2002;41(19):6115\u201327.","journal-title":"Biochemistry."},{"issue":"43","key":"649_CR40","doi-asserted-by":"crossref","first-page":"12451","DOI":"10.1021\/bi701213s","volume":"46","author":"V Rangachari","year":"2007","unstructured":"Rangachari V, Moore BD, Reed DK, Sonoda LK, Bridges AW, Conboy E, et al. Amyloid-\u03b2 (1-42) rapidly forms protofibrils and oligomers by distinct pathways in low concentrations of sodium dodecylsulfate. Biochemistry. 2007;46(43):12451\u201362.","journal-title":"Biochemistry."},{"issue":"16","key":"649_CR41","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1021\/bi0207162","volume":"42","author":"A Case","year":"2003","unstructured":"Case A, Huskey WP, Stein RL. Enzymatic reaction of silent substrates: kinetic theory and application to the serine protease chymotrypsin. Biochemistry. 2003;42(16):4727\u201332.","journal-title":"Biochemistry."},{"issue":"39","key":"649_CR42","doi-asserted-by":"crossref","first-page":"37314","DOI":"10.1074\/jbc.M305627200","volume":"278","author":"MA Leissring","year":"2003","unstructured":"Leissring MA, Lu A, Condron MM, Teplow DB, Stein RL, Farris W, et al. Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays. J Biol Chem. 2003;278(39):37314\u201320.","journal-title":"J Biol Chem"},{"issue":"1","key":"649_CR43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-014-1347-2","volume":"129","author":"HS Nhan","year":"2015","unstructured":"Nhan HS, Chiang K, Koo EH. The multifaceted nature of amyloid precursor protein and its proteolytic fragments: friends and foes. Acta Neuropathol. 2015;129(1):1\u201319.","journal-title":"Acta Neuropathol"},{"issue":"2","key":"649_CR44","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrneurol.2009.218","volume":"6","author":"B De Strooper","year":"2010","unstructured":"De Strooper B, Vassar R, Golde T. The secretases: enzymes with therapeutic potential in Alzheimer disease. Nat Rev Neurol. 2010;6(2):99\u2013107.","journal-title":"Nat Rev Neurol"},{"key":"649_CR45","first-page":"387","volume-title":"The biology of Alzheimer disease","author":"MA Leissring","year":"2011","unstructured":"Leissring MA, Saido TC. Degradation of amyloid-\u03b2 protein. In: Selkoe DJ, Mandelkow E, Holtzman DM, editors. The biology of Alzheimer disease. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press; 2011. p. 387\u2013404."},{"issue":"41","key":"649_CR46","doi-asserted-by":"crossref","first-page":"30471","DOI":"10.1074\/jbc.M605827200","volume":"281","author":"EA Eckman","year":"2006","unstructured":"Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, et al. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem. 2006;281(41):30471\u20138.","journal-title":"J Biol Chem"},{"issue":"7","key":"649_CR47","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/nrn2168","volume":"8","author":"FM LaFerla","year":"2007","unstructured":"LaFerla FM, Green KN, Oddo S. Intracellular amyloid-\u03b2 in Alzheimer\u2019s disease. Nat Rev Neurosci. 2007;8(7):499\u2013509.","journal-title":"Nat Rev Neurosci"},{"issue":"3","key":"649_CR48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1083\/jcb.200110119","volume":"156","author":"Y Zhang","year":"2002","unstructured":"Zhang Y, McLaughlin R, Goodyer C, LeBlanc A. Selective cytotoxicity of intracellular amyloid \u03b2 peptide1-42 through p53 and Bax in cultured primary human neurons. J Cell Biol. 2002;156(3):519\u201329.","journal-title":"J Cell Biol"},{"issue":"2","key":"649_CR49","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/jnc.14048","volume":"142","author":"S Cheng","year":"2017","unstructured":"Cheng S, Wani WY, Hottman DA, Jeong A, Cao D, LeBlanc KJ, et al. Haplodeficiency of cathepsin D does not affect cerebral amyloidosis and autophagy in APP\/PS1 transgenic mice. J Neurochem. 2017;142(2):297\u2013304.","journal-title":"J Neurochem"},{"issue":"1\u20132","key":"649_CR50","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0006-8993(00)03322-9","volume":"893","author":"Y Su","year":"2001","unstructured":"Su Y, Chang PT. Acidic pH promotes the formation of toxic fibrils from beta-amyloid peptide. Brain Res. 2001;893(1\u20132):287\u201391.","journal-title":"Brain Res"},{"issue":"44","key":"649_CR51","doi-asserted-by":"crossref","first-page":"15861","DOI":"10.1523\/JNEUROSCI.3272-11.2011","volume":"31","author":"S Hong","year":"2011","unstructured":"Hong S, Quintero-Monzon O, Ostaszewski BL, Podlisny DR, Cavanaugh WT, Yang T, et al. Dynamic analysis of amyloid \u03b2-protein in behaving mice reveals opposing changes in ISF versus parenchymal A\u03b2 during age-related plaque formation. J Neurosci. 2011;31(44):15861\u20139.","journal-title":"J Neurosci"},{"issue":"29","key":"649_CR52","doi-asserted-by":"crossref","first-page":"30259","DOI":"10.1074\/jbc.M401891200","volume":"279","author":"E Hama","year":"2004","unstructured":"Hama E, Shirotani K, Iwata N, Saido TC. Effects of neprilysin chimeric proteins targeted to subcellular compartments on amyloid \u03b2 peptide clearance in primary neurons. J Biol Chem. 2004;279(29):30259\u201364.","journal-title":"J Biol Chem"},{"issue":"7","key":"649_CR53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1001026","volume":"6","author":"V Khurana","year":"2010","unstructured":"Khurana V, Elson-Schwab I, Fulga TA, Sharp KA, Loewen CA, Mulkearns E, et al. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo. PLoS Genet. 2010;6(7):e1001026.","journal-title":"PLoS Genet"},{"key":"649_CR54","doi-asserted-by":"publisher","unstructured":"Qureshi YH, Patel VM, Berman DE, Kothiya MJ, Neufeld JL, Vardarajan B, Tang M, Reyes-Dumeyer D, Lantigua R, Medrano M, Jim\u00e9nez-Vel\u00e1zquez IJ, Small SA, Reitz C. An Alzheimer's Disease-Linked Loss-of-Function CLN5 Variant Impairs Cathepsin D Maturation, Consistent with a Retromer Trafficking Defect. Mol Cell Biol. 2018;38(20):e00011-18. https:\/\/doi.org\/10.1128\/MCB.00011-18.","DOI":"10.1128\/MCB.00011-18"},{"issue":"3","key":"649_CR55","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/0959-8049(94)90261-5","volume":"30A","author":"I Touitou","year":"1994","unstructured":"Touitou I, Capony F, Brouillet JP, Rochefort H. Missense polymorphism (C\/T224) in the human cathepsin D pro-fragment determined by polymerase chain reaction--single strand conformational polymorphism analysis and possible consequences in cancer cells. Eur J Cancer. 1994;30A(3):390\u20134.","journal-title":"Eur J Cancer"},{"issue":"1","key":"649_CR56","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/ng1934","volume":"39","author":"L Bertram","year":"2007","unstructured":"Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet. 2007;39(1):17\u201323.","journal-title":"Nat Genet"},{"issue":"4","key":"649_CR57","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0092-8674(95)90073-X","volume":"81","author":"H Zheng","year":"1995","unstructured":"Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW, et al. \u03b2-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell. 1995;81(4):525\u201331.","journal-title":"Cell."},{"issue":"3","key":"649_CR58","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/85059","volume":"4","author":"Y Luo","year":"2001","unstructured":"Luo Y, Bolon B, Kahn S, Bennett BD, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer\u2019s \u03b2-secretase, have normal phenotype and abolished \u03b2-amyloid generation. Nat Neurosci. 2001;4(3):231\u20132.","journal-title":"Nat Neurosci"},{"issue":"8","key":"649_CR59","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1096\/fj.05-5530fje","volume":"20","author":"F Chen","year":"2006","unstructured":"Chen F, Eckman EA, Eckman CB. Reductions in levels of the Alzheimer\u2019s amyloid beta peptide after oral administration of ginsenosides. FASEB J. 2006;20(8):1269\u201371.","journal-title":"FASEB J"},{"key":"649_CR60","doi-asserted-by":"crossref","first-page":"117793221882138","DOI":"10.1177\/1177932218821383","volume":"13","author":"SD Kramer","year":"2019","unstructured":"Kramer SD, Wohrle J, Rath C, Roth G. Anabel: an online tool for the real-time kinetic analysis of binding events. Bioinform Biol Insights. 2019;13:1177932218821383.","journal-title":"Bioinform Biol Insights"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-020-00649-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-020-00649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T20:22:43Z","timestamp":1625516563000},"score":1,"resource":{"primary":{"URL":"https:\/\/alzres.biomedcentral.com\/articles\/10.1186\/s13195-020-00649-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,6]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1186\/s13195-020-00649-8","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,6]]},"assertion":[{"value":"6 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animals used in this study were utilized in accordance with the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals, with the consent of Institutional Animal Care and Use Committees.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"80"}}